Vile RG - Search Results

1

Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.

Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K. Galanis E, et al. Among authors: vile rg. Mol Ther. 2012 Oct;20(10):1998-2003. doi: 10.1038/mt.2012.146. Epub 2012 Aug 7. Mol Ther. 2012. PMID: 22871663 Free PMC article. Clinical Trial.

2

Transcriptional control: an essential component of cancer gene therapy strategies?

Harrington KJ, Linardakis E, Vile RG. Harrington KJ, et al. Among authors: vile rg. Adv Drug Deliv Rev. 2000 Nov 15;44(2-3):167-84. doi: 10.1016/s0169-409x(00)00093-4. Adv Drug Deliv Rev. 2000. PMID: 11072113 Review.

3

Cancer gene therapy: developments to 2000.

Bateman AR, Harrington KJ, Melcher AA, Vile RG. Bateman AR, et al. Among authors: vile rg. Expert Opin Investig Drugs. 2000 Dec;9(12):2799-813. doi: 10.1517/13543784.9.12.2799. Expert Opin Investig Drugs. 2000. PMID: 11093354 Review.

4

Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy.

Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ. Higuchi H, et al. Among authors: vile rg. Cancer Res. 2000 Nov 15;60(22):6396-402. Cancer Res. 2000. PMID: 11103804

5

Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.

Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ. Galanis E, et al. Hum Gene Ther. 2001 May 1;12(7):811-21. doi: 10.1089/104303401750148766. Hum Gene Ther. 2001. PMID: 11339897

6

Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors.

Galanis E, Vile R, Russell SJ. Galanis E, et al. Crit Rev Oncol Hematol. 2001 Jun;38(3):177-92. doi: 10.1016/s1040-8428(01)00103-2. Crit Rev Oncol Hematol. 2001. PMID: 11369253 Review.

7

Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer.

Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, Peters AM, Stewart JS. Harrington KJ, et al. Among authors: vile rg. Ann Oncol. 2001 Apr;12(4):493-6. doi: 10.1023/a:1011199028318. Ann Oncol. 2001. PMID: 11398881 Free article. Clinical Trial.

8

A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.

Emiliusen L, Gough M, Bateman A, Ahmed A, Voellmy R, Chester J, Diaz RM, Harrington K, Vile R. Emiliusen L, et al. Gene Ther. 2001 Jul;8(13):987-98. doi: 10.1038/sj.gt.3301470. Gene Ther. 2001. PMID: 11438833

9

Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy.

Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. Spitzweg C, et al. Among authors: vile rg. J Clin Endocrinol Metab. 2001 Jul;86(7):3327-35. doi: 10.1210/jcem.86.7.7641. J Clin Endocrinol Metab. 2001. PMID: 11443208 Review. No abstract available.

10

Gene therapy for prostate cancer: current status and future prospects.

Harrington KJ, Spitzweg C, Bateman AR, Morris JC, Vile RG. Harrington KJ, et al. Among authors: vile rg. J Urol. 2001 Oct;166(4):1220-33. doi: 10.1016/s0022-5347(05)65742-4. J Urol. 2001. PMID: 11547047 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

295 results

Search Page